Jia FanProfessor


Academician of Chinese Academy of Sciences;

President, Zhongshan Hospital, Fudan University


  Work Experience

Dr Jia Fan is an Academician of Chinese Academy of Sciences, president of Zhongshan Hospital, vice-director of Liver Cancer Institute, Fudan University. He is also a professor of liver surgery and director of department of Oncology and Organ Transplantation Center, Zhongshan Hospital, Fudan University.

  Research Interests

Professor Jia Fan dedicated in clinical diagnosis, treatment and basic research of liver cancer. His major contributions in liver cancer study are as follows: He has performed more than 9000 cases of liver resection for liver cancer, and successfully performed liver transplantation for more than 2200 cases. He extended the Milan criteria to “Shanghai-Fudan criteria” in HCC patients. In basic research, his group identified a plasma microRNA panel, which has translated to clinical usage successfully for the early diagnosis of HCC. In study of liver cancer metastasis, his group discovered a variety of new mechanisms, including identification of novel predictors, therapeutic targets, as well as the role of the tumor microenvironment in HCC metastasis. So far, he has published more than 140 papers as the first or the corresponding author in SCI journals, such as Nature, Lancet Oncology, J Clinical Oncology, Gastroenterology and Hepatology.


He was awarded two second class prizes of the State Science and Technology Awards for his outstanding contribution in comprehensive management of portal vein tumor thrombosis of HCC and prevention and treatment strategies of tumor recurrence following liver transplantation. He also was awarded the first prize of natural science of Ministry of Education for his basic research in HCC tumor microenvironment.

  Selected Publications

1. Gao Q, Qiu SJ,Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma following resection.Journal of Clinical Oncology. 2007, 25(18):2586-93.

2. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H,Fan J. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.J Clin Oncol. 2011;29(36):4781-8.

3. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB, Wang XY, Devbhandari RP,Fan J. CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells.Gastroenterology. 2011;140(5):1629-41.e15.

4. Sun YF, Xu Yang, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, Hu B, Zhou J,Fan J. Circulating Stem Cell–Like Epithelial Cell Adhesion Molecule–Positive Tumor Cells Indicate Poor Prognosis of Hepatocellular Carcinoma After Curative Resection.Hepatology, 2013, 57(4): 1458-1468.

5. Gao Q, Wang ZC, Duan M, Lin YH, Zhou XY, Worthley DL, Wang XY, Niu G, Xia Y, Deng M, Liu LZ, Shi JY, Yang LX, Zhang S, Ding ZB, Zhou J, Liang CM, Cao Y, Xiong L, Xi R, Shi YY,Fan J. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.Gastroenterology. 2017 Jan;152(1):232-242.